TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05740917
Drug: XZB-0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: XZB-0004 orally Twice daily of every 28-day cycle
Study: NCT04821323
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin capsules will be administered orally.
Study: NCT06095791
Drug: Immunomodulators with FDA approval on the 1st January 2023.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
Study: NCT05798416
Drug: Exercise under inhalation CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
Study: NCT05352828
Drug: Autologous CD30.CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 2 x 10e8 cells/m2
Study: NCT00324831
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00324831
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04738773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04315636
Drug: Surfactant nebulisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
Study: NCT05215743
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy
Study: NCT05215743
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05420246
Drug: Ainuovirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
Study: NCT05620576
Drug: LY3857210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05620576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05565768
Drug: HZN-457
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZN-457 will be given in one subcutaneous administration
Study: NCT05565768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in one subcutaneous administration
Study: NCT00487123
Drug: Valsartan+/- Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05905484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of matching placebo will be administered.
Study: NCT04064346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04784533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing
Study: NCT05978102
Drug: Standard treatment（SoC）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
Study: NCT06172920
Drug: Aldolan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are receiving meperidine under thoracic surgery
Study: NCT00002342
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05439876
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 2 mg daily for 4 weeks
Study: NCT05439876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 4 weeks
Study: NCT04732949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
Study: NCT05141721
Drug: GRT-C901
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
Study: NCT05141721
Drug: GRT-R902
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
Study: NCT05141721
Drug: Fluoropyrimidine plus leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
Study: NCT05164458
Drug: IBI 308 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI308 IV 200mg Q3W Day1
Study: NCT05164458
Drug: IBI 389 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI 389 IV Q2\~Q3W Day 1
Study: NCT04836299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive a single of placebo.
Study: NCT04809220
Drug: Oral antihyperglycemics
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05471050
Drug: TAC
Normalized name: TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
Study: NCT05354128
Drug: Thrombolytic
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous thrombolysis.
Study: NCT05687435
Drug: Changyanning tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation.
Study: NCT06063486
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05242081
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
Study: NCT05407987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
Study: NCT04829487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT05351346
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT05351346
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT04026984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablets
Study: NCT05277246
Drug: NaOCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaOCI
Study: NCT05349149
Drug: Saline 9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
Study: NCT04917055
Drug: ropivacaine 0.25% with epinephrine and 6mg dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
Study: NCT02434835
Drug: [14C]KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05625035
Drug: Lianhua Qingwen capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhua Qingwen capsules: 4 capsules once, three times daily
Study: NCT06300333
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
Study: NCT00000796
Drug: Streptomycin sulfate
Normalized name: Streptomycin Sulfate
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000796
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000796
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04685564
Drug: RBD1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission.
Study: NCT04685564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same as RBD1016
Study: NCT06130332
Drug: PD-1 with chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor
Study: NCT04847388
Drug: Substance like alcohol, marijuana, etc.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort study
Study: NCT05377528
Drug: AGEN1571
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
Study: NCT05813158
Drug: Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
Study: NCT05813158
Drug: Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
Study: NCT04327986
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) on Days 1 and 15 of every cycle
Study: NCT06492811
Drug: GAT@F nanoenzyme hydrogel complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
Study: NCT05366439
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel Assignment
Study: NCT04145258
Drug: Placebo of aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Study: NCT04145258
Drug: WHO TBM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months of (R-H-Z-E) + 7 months of (R-H)
Study: NCT04145258
Drug: Intensified TBM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
Study: NCT05563064
Drug: Karika Syrup
Normalized name: Phragmites karka whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
Study: NCT04916795
Drug: Vupanorsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg subcutaneous injection
Study: NCT05769959
Drug: RO7515629
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
Study: NCT05507983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, sodium chloride 0.9%
Study: NCT05768477
Drug: Baxter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine or Linisol baxter therapy
Study: NCT04988217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized placebo
Study: NCT05346224
Drug: EU-Perjeta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
Study: NCT04944901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral formulation
Study: NCT05041933
Drug: outsourcing of chemotherapy to Hospital at Home
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: outsourcing of chemotherapy to Hospital at Home
Study: NCT05277311
Drug: LongShengZhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: LongShengZhi capsules, orally, 5 capsules each time, three times a day.
Study: NCT05277311
Drug: LongShengZhi capsule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
Study: NCT05595993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive oral administration of placebo.
Study: NCT05861505
Drug: Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation
Study: NCT05437289
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
Study: NCT05437289
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
Study: NCT05437289
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
Study: NCT05437289
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
Study: NCT05324163
Drug: X0002 Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
Study: NCT05324163
Drug: Celecoxib capsules
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
Study: NCT05324163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
Study: NCT04743661
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
Study: NCT04743661
Drug: Antipyretic
Normalized name: ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
Study: NCT04743661
Drug: anti-emetics
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
Study: NCT05547321
Drug: OMTX705
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is OMTX705 administered as monotherapy.
Study: NCT00430092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06212102
Drug: Progestin primed ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
Study: NCT05372120
Drug: ICP-192
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
Study: NCT05210790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05369858
Drug: [14C] SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
Study: NCT04964453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
Study: NCT05128175
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
Study: NCT05862064
Drug: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy in combination with carrelizumab
Study: NCT05862064
Drug: epirubicin,cyclophosphamide,paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy
Study: NCT05017610
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05873465
Drug: Sedation with Midazolam, Fentanyl, and Propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
Study: NCT05876039
Drug: Initial remifentanil effect-site concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different initial remifentanil effect-site concentration
Study: NCT05543590
Drug: Plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sessions of plasma exchanges
Study: NCT05970432
Drug: TQH2722 injection 300mg-150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
Study: NCT05970432
Drug: TQH2722 injection 600mg-300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
Study: NCT05970432
Drug: TQH2722 injection 900mg-450mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
Study: NCT05970432
Drug: TQH2722 injection matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without active substance.
Study: NCT06183008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days